Kura Oncology, Inc.

NasdaqGS:KURA Rapporto sulle azioni

Cap. di mercato: US$836.0m

Kura Oncology Gestione

Gestione criteri di controllo 3/4

Kura Oncology Il CEO è Troy Wilson, nominato in Mar2015, e ha un mandato di 9.67 anni. la retribuzione annua totale è $ 5.25M, composta da 12.3% di stipendio e 87.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.75% delle azioni della società, per un valore di $ 6.23M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4 anni e 9.1 anni.

Informazioni chiave

Troy Wilson

Amministratore delegato

US$5.3m

Compenso totale

Percentuale dello stipendio del CEO12.3%
Mandato del CEO9.7yrs
Proprietà del CEO0.7%
Durata media del management4yrs
Durata media del Consiglio di amministrazione9.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Kura Oncology: A Contender In The Field Of Precision Medicine

Nov 21

Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry?

Nov 01
Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry?

Kura Oncology: The Long Holding Pattern Is Risky

Aug 12

Estimating The Fair Value Of Kura Oncology, Inc. (NASDAQ:KURA)

Jul 12
Estimating The Fair Value Of Kura Oncology, Inc. (NASDAQ:KURA)

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

May 08
Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Kura Oncology: Balancing Act Of Promise And Pragmatism

May 07

Kura Oncology: Ziftomenib's Path To AML Market Widens

Jan 31

Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price

Jan 25
Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price

Is Kura Oncology (NASDAQ:KURA) A Risky Investment?

Aug 14
Is Kura Oncology (NASDAQ:KURA) A Risky Investment?

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Apr 04
Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?

Jan 31
Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?

Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans

Oct 10
Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans

Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating

Jul 13

We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth

Jun 26
We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Nov 23
We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Aug 09
We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Kura Oncology Investor Presentation - Slideshow

May 08

What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?

Dec 14
What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?

Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks

Dec 10

Kura Oncology (KURA) Presents At ASH Virtual Investor Event

Dec 08

Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate

Dec 07

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Troy Wilson rispetto agli utili di Kura Oncology?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$198m

Jun 30 2024n/an/a

-US$182m

Mar 31 2024n/an/a

-US$168m

Dec 31 2023US$5mUS$646k

-US$153m

Sep 30 2023n/an/a

-US$143m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$137m

Dec 31 2022US$5mUS$621k

-US$136m

Sep 30 2022n/an/a

-US$135m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022n/an/a

-US$132m

Dec 31 2021US$9mUS$600k

-US$130m

Sep 30 2021n/an/a

-US$124m

Jun 30 2021n/an/a

-US$114m

Mar 31 2021n/an/a

-US$101m

Dec 31 2020US$4mUS$573k

-US$90m

Sep 30 2020n/an/a

-US$81m

Jun 30 2020n/an/a

-US$74m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$3mUS$542k

-US$63m

Sep 30 2019n/an/a

-US$61m

Jun 30 2019n/an/a

-US$60m

Mar 31 2019n/an/a

-US$60m

Dec 31 2018US$5mUS$526k

-US$60m

Sep 30 2018n/an/a

-US$55m

Jun 30 2018n/an/a

-US$49m

Mar 31 2018n/an/a

-US$43m

Dec 31 2017US$2mUS$472k

-US$35m

Compensazione vs Mercato: La retribuzione totale di Troy ($USD 5.25M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.15M ).

Compensazione vs guadagni: La retribuzione di Troy è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Troy Wilson (55 yo)

9.7yrs

Mandato

US$5,251,407

Compensazione

Dr. Troy Edward Wilson, Ph D., J.D., is Independent Director of Cartography Biosciences, Inc. from October 2024. He is Co-Founder of Avidity Biosciences Inc. and had been its Executive Chairman since Febru...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Troy Wilson
Chairman9.7yrsUS$5.25m0.75%
$ 6.2m
Kathleen Ford
Chief Operating Officer5.3yrsUS$2.16m0.016%
$ 131.5k
Teresa Bair
Chief Legal Officer & Corporate Secretary3.1yrsUS$1.98m0.0069%
$ 57.8k
Stephen Dale
Chief Medical Officer4.3yrsUS$2.47m0.0039%
$ 32.5k
Thomas Doyle
Senior Vice President of Finance & Accounting2.8yrsNessun dato0.015%
$ 127.7k
Pete De Spain
Executive Vice President of Investor Relations & Corporate Communications7.1yrsNessun datoNessun dato
Roger Bakale
Senior Vice President of Manufacturing & Supply Chain4.8yrsNessun datoNessun dato
Maureen Clancy
VP and Global Head of Program Leadership & Project Management3.7yrsNessun datoNessun dato
Mollie Leoni
Executive Vice President of Clinical Development2.8yrsNessun datoNessun dato
Brian Powl
Chief Commercial Officer1.3yrsNessun datoNessun dato
Francis Burrows
Senior Vice President of Translational Researchno dataNessun datoNessun dato

4.0yrs

Durata media

53yo

Età media

Gestione esperta: Il team dirigenziale di KURA è considerato esperto (durata media dell'incarico 4 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Troy Wilson
Chairman9.7yrsUS$5.25m0.75%
$ 6.2m
Daniel Von Hoff
Clinical Advisorno dataNessun datoNessun dato
Thomas Malley
Independent Director9.1yrsUS$275.69k0%
$ 0
Mary Szela
Independent Director6yrsUS$279.80k0%
$ 0
Faheem Hasnain
Lead Independent Director9.6yrsUS$300.54k0.031%
$ 257.8k
Frank McCormick
Scientific Advisorno dataNessun datoNessun dato
Neal Rosen
Scientific Advisorno dataNessun datoNessun dato
Kevan Shokat
Chairman of the Scientific Advisory Boardno dataNessun datoNessun dato
Alan Houghton
Clinical Advisorno dataNessun datoNessun dato
Josep Tabernero
Clinical Advisorno dataNessun datoNessun dato
Steven Horwitz
Clinical Advisorno dataNessun datoNessun dato
Carol Schafer
Independent Director3.4yrsUS$279.05k0%
$ 0

9.1yrs

Durata media

63.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di KURA sono considerati esperti (durata media dell'incarico 9.1 anni).